In this study, 2275 clinical isolates of 49 species of non-tuberculous mycobacteria isolated in The Netherlands were subjected to standardised drug susceptibility testing using the Middlebrook 7H10 agar dilution method.
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A c c e p t e d M a n u s c r i p t ABSTRACT In this study, 2275 clinical isolates of 49 species of non-tuberculous mycobacteria isolated in The Netherlands were subjected to standardised drug susceptibility testing using the Middlebrook 7H10 agar dilution method.
Clarithromycin and rifabutin were most active, with 87% and 83% of all isolates, respectively, being susceptible. Susceptibility to ciprofloxacin (44%) and amikacin (32%) was limited and was mostly restricted to Mycobacterium kansasii, Mycobacterium xenopi, Mycobacterium fortuitum and phylogenetically related species. Susceptibility to isoniazid (0.5%), rifampicin (37%), ethambutol (35%) and streptomycin (33%) was rare; susceptibility to cycloserine, clofazimine and prothionamide was generally restricted to slow growers, although prothionamide also had activity against M. fortuitum and related species. Significant discrepancies between in vitro and in vivo activity exist. To improve the utility of drug susceptibility testing, the selection of drugs should be changed to more drugs with proven clinical efficacy correlating with in vitro susceptibility. M a n u s c r i p t
Introduction
There is an increasing number of clinical isolates of non-tuberculous mycobacteria (NTM) in many countries as well as a growing awareness of their ability to cause disease [1, 2] . NTM are opportunistic pathogens that can occasionally cause severe disease, usually in patients with pre-existing pulmonary disease or systemic impairment of immunity [1] .
Treatment of NTM disease is time consuming and often complicated.
Macrolide-based multidrug regimens are currently advocated by the American Thoracic Society (ATS) [1] . In a recent trial of the British Thoracic Society (BTS), no beneficial effect of macrolides on treatment of patients with pulmonary Mycobacterium avium complex (MAC), Mycobacterium malmoense and Mycobacterium xenopi disease was found [3] . Few clinical trials have been conducted, especially for disease due to less prevalent NTM species; current guidelines are mainly based on case reports and clinical experience.
Although there is a lack of correlation between in vitro drug susceptibility testing (DST) results and in vivo treatment outcome, DST is valuable, especially in patients with no response to first-line treatment or with a relapse of prior NTM disease [1] . For many of the infrequently isolated NTM species, no DST results have been published and there is little basis to predict potentially successful treatment regimens.
A variety of DST methods have been applied to NTM. The Clinical and Laboratory Standards Institute (CLSI) currently recommends broth-based A c c e p t e d M a n u s c r i p t methods for MAC and related slow-growing NTM, with the broth microdilution technique also considered suitable for rapid growers [4] . Application of these techniques has highlighted the therapeutic potential of the macrolides, linezolid and tigecycline for disease due both to slow-and rapid-growing NTM [1, 4] .
In The Netherlands, a Middlebrook 7H10 agar dilution method has been used for over a decade with favourable results for Mycobacterium tuberculosis complex isolates [5] . This study reports the DST results on a wide variety of NTM isolated from clinical samples in The Netherlands and discusses the implications of these findings for NTM treatment regimens.
Materials and methods
DST results of all clinical NTM isolates subjected to laboratory diagnosis at For each series of isolates inoculated on DST plates, one Mycobacterium gordonae strain, one M. avium strain and three M. tuberculosis control strains that have been extensively characterised by our own laboratory were included as internal controls [5] . As a second-line quality control, strains were exchanged in a blind fashion with a peripheral laboratory and re-tested to check reproducibility.
Results
DST was performed on 2275 isolates of 49 different NTM species or complexes isolated from 2072 patients. The results obtained for published species of which five or more isolates were tested (2240 isolates of 29 species or complexes) are detailed qualitatively in Table 1 . For this analysis, strains exhibiting intermediate susceptibility to isoniazid and ethambutol were considered resistant. The median MICs measured for all isolates are recorded in Table 2 . The results obtained in the less frequent (n < 5) species are recorded in Table 3 .
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Isolates of most species were found to be susceptible to clarithromycin, most notably among the slow-growing NTM. Resistance to clarithromycin was only noted in the majority of Mycobacterium simiae, Mycobacterium mageritense and M. fortuitum isolates (Tables 1 and 2 In vitro susceptibility to first-line antituberculosis drugs, especially isoniazid and rifampicin, was found to be rare among NTM. However, susceptibility to rifabutin was frequent ( Table 1 
Discussion
Analysing the results of 7 years of DST for NTM using the 25-well agar dilution method, it is evident that the results yield important clues for optimisation of NTM species-specific therapy.
The debate on the role of DST in the management of NTM disease is ongoing, mainly because of the observed discrepancies between in vitro susceptibility and in vivo response to treatment [1, 3, 6, 7] . These discrepancies need further study, especially for the newer antimicrobial drugs and the less frequently isolated NTM species. Baseline testing for specific drugs such as rifampicin for M. kansasii and clarithromycin for MAC isolates helps to understand treatment failure or relapse and thereafter to select second-line treatment regimens [1, 4] . A c c e p t e d M a n u s c r i p t ethambutol only [7] . However, a recent comparative trial of 2 years of rifampicin, ethambutol and clarithromycin or ciprofloxacin for pulmonary MAC, M. malmoense and M. xenopi disease was unable to demonstrate superiority of either triple-drug regimen drug over the rifampicin and ethambutol only regimen [3, 6] . In this trial, in vitro susceptibility to ciprofloxacin or clarithromycin was not assessed [3] . We found frequent ciprofloxacin resistance among MAC (92-99%) and M. malmoense (74%) ( Table 1) strains.
Whilst casting doubt on the efficacy of ciprofloxacin, our results offer no explanation for the limited results in patients receiving a macrolide-based regimen in the BTS study [3] . This illustrates the necessity to acquire more clinical data that establish the correlation between in vitro and in vivo activity.
There could be a role for macrolides in the case of first-line treatment failure or relapse with susceptible strains.
Although clarithromycin resistance in primary isolates was rare, 9% (22/237) of our patients with serial isolates had clarithromycin-resistant secondary isolates. In vitro resistance to macrolides has been related to poor in vivo treatment outcome [1, 6] .
For the macrolide-resistant species in our study, in vitro susceptibility to ciprofloxacin indicates a possible role for the fluoroquinolones. Most M. simiae isolates, however, are also resistant to ciprofloxacin (Table 1) . Treatment results in M. simiae disease are, probably as a result, poor [8] .
The common in vitro resistance to ciprofloxacin (Table 1 ) may explain its limited in vivo activity in the latest BTS trial [3] . Moxifloxacin is more active in vitro than ciprofloxacin [1] and may be active against isolates that have median MICs just above the ciprofloxacin breakpoint (M. malmoense, M. chelonae). Combination therapy of moxifloxacin and clarithromycin may not be advisable as fluoroquinolones were recently demonstrated to attenuate clarithromycin activity in a murine model of MAC disease [9] . How this translates to human disease remains to be determined.
The widespread amikacin resistance is contrary to results available in the literature, at least for M. avium and M. abscessus [1, 4] . The discrepancies, which may result from the test methods or the applied breakpoint concentrations, are awkward since better sputum conversion rates have been recorded in patients receiving an aminoglycoside as adjunctive therapy for MAC disease [1, 6] . Hence, reporting false amikacin resistance may negatively affect therapy choice and outcome.
In vitro susceptibility to cycloserine, prothionamide and clofazimine was common, especially among slow-growing NTM. However, the efficacy of these drugs in NTM treatment has not been sufficiently proven and they are limited by their toxicity [1, 10, 11] . gene confers inducible macrolide resistance [1, 13] . The high levels of intrinsic drug resistance may also result from the existence of multidrug efflux pumps [14] .
Similar DST results may hint at a phylogenetic relationship between various species, for example M. kansasii, M. szulgai and M. marinum (Tables 1 and   2 ). The phylogenetic relationship of these species was also observed in a multigene taxonomical model [15] . M a n u s c r i p t M a n u s c r i p t 1 M a n u s c r i p t A c c e p t e d M a n u s c r i p t 1 A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 1   Table 3 Drug susceptibility testing results of seldom encountered non-tuberculous mycobacteria (n < 
